DYN Dyne Therapeutics
- 29.330
- +1.200+4.27%
- 29.330
- 0.0000.00%
Dyne Therapeutics News
Dyne Therapeutics Analyst Ratings
J.P. Morgan Downgrades Dyne Therapeutics(DYN.US) to Hold Rating, Cuts Target Price to $35
Dyne Therapeutics Downgraded to Neutral From Overweight at JPMorgan
Morgan Stanley Maintains Dyne Therapeutics(DYN.US) With Buy Rating, Maintains Target Price $52
Analysts' Top Healthcare Picks: 10x Genomics (TXG), Dyne Therapeutics (DYN)
Dyne Therapeutics Analyst Ratings
Piper Sandler Maintains Dyne Therapeutics(DYN.US) With Buy Rating, Maintains Target Price $53
Piper Sandler Sticks to Its Buy Rating for Dyne Therapeutics (DYN)
H.C. Wainwright Maintains Dyne Therapeutics(DYN.US) With Buy Rating, Maintains Target Price $55
A Quick Look at Today's Ratings for Dyne Therapeutics(DYN.US), With a Forecast Between $50 to $55
Dyne Therapeutics Price Target Maintained With a $55.00/Share by HC Wainwright & Co.
Dyne Therapeutics Analyst Ratings
Buy Rating Affirmed Amidst Dose Adjustments and Promising Trial Results for Dyne Therapeutics
Stifel Maintains Dyne Therapeutics(DYN.US) With Buy Rating, Raises Target Price to $66
Dyne Therapeutics Analyst Ratings
Morgan Stanley Maintains Dyne Therapeutics(DYN.US) With Buy Rating, Maintains Target Price $52
A Quick Look at Today's Ratings for Dyne Therapeutics(DYN.US), With a Forecast Between $52 to $55
Morgan Stanley Maintains Overweight on Dyne Therapeutics, Raises Price Target to $52
A Quick Look at Today's Ratings for Dyne Therapeutics(DYN.US), With a Forecast Between $50 to $55
Dyne Therapeutics (DYN) Receives a Buy From Piper Sandler
Analysis
Price Target
No Data
No Data